ONX-0914 (PR-957)
To Order Contact us: [email protected]
ONX-0914 (PR-957) |
|||
| MBS578604-5mg | MyBiosource | 5mg | EUR 210 |
ONX-0914 (PR-957) |
|||
| MBS578604-5x10mg | MyBiosource | 5x10mg | EUR 1080 |
ONX-0914 |
|||
| 205730 | MedKoo Biosciences | 5.0mg | EUR 150 |
ONX-0914 |
|||
| 2555-25 | Biovision | each | EUR 810 |
ONX-0914 |
|||
| 2555-5 | Biovision | each | EUR 248.4 |
ONX-0914 |
|||
| HY-13207 | MedChemExpress | 10mM/1mL | EUR 811.7 |
|
Description: ONX-0914 (PR-957) is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (Ki=5.2 μM). ONX-0914 reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1[1][2][3]. |
|||
ONX-0914 |
|||
| MBS385861-10mg | MyBiosource | 10mg | EUR 240 |
ONX-0914 |
|||
| MBS385861-1mLinDMSO | MyBiosource | 1mL(inDMSO) | EUR 230 |
ONX-0914 |
|||
| MBS385861-25mg | MyBiosource | 25mg | EUR 405 |
ONX-0914 |
|||
| MBS385861-50mg | MyBiosource | 50mg | EUR 580 |
ONX-0914 |
|||
| MBS385861-5mg | MyBiosource | 5mg | EUR 190 |
ONX-0914 |
|||
| MBS3606851-10mg | MyBiosource | 10mg | EUR 225 |
ONX-0914 |
|||
| MBS3606851-50mg | MyBiosource | 50mg | EUR 350 |
ONX-0914 |
|||
| MBS3606851-5mg | MyBiosource | 5mg | EUR 210 |
ONX-0914 |
|||
| MBS3606851-5x50mg | MyBiosource | 5x50mg | EUR 1255 |
ONX-0914 |
|||
| T6029-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: ONX-0914 |
|||
ONX-0914 |
|||
| T6029-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: ONX-0914 |
|||
ONX-0914 |
|||
| T6029-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: ONX-0914 |
|||
ONX-0914 |
|||
| T6029-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: ONX-0914 |
|||
ONX-0914 |
|||
| T6029-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: ONX-0914 |
|||
ONX 0914 |
|||
| GW4334 | Glentham Life Sciences | 1mg | EUR 489.72 |
ONX 0914 |
|||
| GW4334-1 | Glentham Life Sciences | 1 | EUR 98.4 |
ONX 0914 |
|||
| GW4334-25 | Glentham Life Sciences | 25 | EUR 534.9 |
ONX 0914 |
|||
| GW4334-5 | Glentham Life Sciences | 5 | EUR 198.6 |
ONX 0914 |
|||
| O658000 | Toronto Research Chemicals | 100mg | EUR 138 |
|
Description: 960374-59-8 |
|||
ONX 0914 |
|||
| TRC-O658000-100MG | Toronto Research Chemicals | 100 mg | Ask for price |
ONX 0914 |
|||
| TRC-O658000-5MG | Toronto Research Chemicals | 5 mg | Ask for price |
ONX 0914 |
|||
| TRC-O658000-25MG | Toronto Research Chemicals | 25 mg | Ask for price |
ONX-0914 (TFA) |
|||
| HY-13207A | MedChemExpress | 10 mg | EUR 102.82 |
|
Description: ONX-0914 (PR-957) TFA is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 TFA blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 TFA is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (Ki=5.2 μM). ONX-0914 TFA reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1[1][2][3]. |
|||
Oprozomib (ONX-0912) |
|||
| A1934-10 | ApexBio | 10 mg | EUR 128 |
|
Description: Ubiquitination/ Proteasome|Proteasome |
|||
Oprozomib (ONX-0912) |
|||
| A1934-25 | ApexBio | 25 mg | EUR 240 |
|
Description: Ubiquitination/ Proteasome|Proteasome |
|||
Oprozomib (ONX-0912) |
|||
| A1934-5 | ApexBio | 5 mg | EUR 84 |
|
Description: Ubiquitination/ Proteasome|Proteasome |
|||
Oprozomib (ONX-0912) |
|||
| A1934-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 112.8 |
|
Description: Ubiquitination/ Proteasome|Proteasome |
|||
Oprozomib, ONX-0912 |
|||
| MBS132460-100mg | MyBiosource | 100mg | EUR 1065 |
Oprozomib, ONX-0912 |
|||
| MBS132460-500mg | MyBiosource | 500mg | EUR 2775 |
Oprozomib (ONX 0912) |
|||
| 205565 | MedKoo Biosciences | 10.0mg | EUR 150 |
ONX 0801 (trisodium) |
|||
| HY-10822A | MedChemExpress | Get quote | Ask for price |
|
Description: ONX 0801 (BGC 945) trisodium is a thymidylate synthase (TS) inhibitor, targeted to α-folate receptor–overexpressing tumors[1][2]. |
|||
Oprozomib [ONX 0912] |
|||
| GW2060 | Glentham Life Sciences | 1mg | EUR 433.73 |
Oprozomib [ONX 0912] |
|||
| GW2060-1 | Glentham Life Sciences | 1 | EUR 86.5 |
Oprozomib [ONX 0912] |
|||
| GW2060-25 | Glentham Life Sciences | 25 | EUR 428.6 |
Oprozomib [ONX 0912] |
|||
| GW2060-5 | Glentham Life Sciences | 5 | EUR 169 |
ONX 0912 (Oprozomib) |
|||
| MBS385863-10mg | MyBiosource | 10mg | EUR 245 |
ONX 0912 (Oprozomib) |
|||
| MBS385863-1mLinDMSO | MyBiosource | 1mL(inDMSO) | EUR 230 |
ONX 0912 (Oprozomib) |
|||
| MBS385863-25mg | MyBiosource | 25mg | EUR 405 |
ONX 0912 (Oprozomib) |
|||
| MBS385863-5mg | MyBiosource | 5mg | EUR 195 |
ONX 0912 (Oprozomib) |
|||
| MBS385863-5x25mg | MyBiosource | 5x25mg | EUR 1815 |
ONX 0801 trisodium |
|||
| MBS5785395-5mg | MyBiosource | 5(mg | EUR 3225 |
ONX 0801 trisodium |
|||
| MBS5785395-5x5mg | MyBiosource | 5x5(mg | EUR 14370 |
Oprozomib (ONX 0912) |
|||
| MBS578616-10mg | MyBiosource | 10mg | EUR 210 |
Oprozomib (ONX 0912) |
|||
| MBS578616-25mg | MyBiosource | 25mg | EUR 330 |
Oprozomib (ONX 0912) |
|||
| MBS578616-2mg | MyBiosource | 2mg | EUR 150 |
Oprozomib (ONX 0912) |
|||
| MBS578616-5mg | MyBiosource | 5mg | EUR 180 |
Oprozomib (ONX 0912) |
|||
| MBS578616-5x25mg | MyBiosource | 5x25mg | EUR 1325 |
ONX 0801 trisodium |
|||
| T38490-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: ONX 0801 trisodium |
|||
ONX 0801 trisodium |
|||
| T38490-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: ONX 0801 trisodium |
|||
ONX 0801 trisodium |
|||
| T38490-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: ONX 0801 trisodium |
|||
ONX 0801 trisodium |
|||
| T38490-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: ONX 0801 trisodium |
|||
ONX 0801 trisodium |
|||
| T38490-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: ONX 0801 trisodium |
|||
AHR-0914 |
|||
| MBS5779379-5mg | MyBiosource | 5(mg | EUR 915 |
AHR-0914 |
|||
| MBS5779379-5x5mg | MyBiosource | 5x5(mg | EUR 3970 |
AHR-0914 |
|||
| T29747-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: AHR-0914 |
|||
AHR-0914 |
|||
| T29747-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: AHR-0914 |
|||
AHR-0914 |
|||
| T29747-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: AHR-0914 |
|||
AHR-0914 |
|||
| T29747-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: AHR-0914 |
|||
AHR-0914 |
|||
| T29747-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: AHR-0914 |
|||
ACY-957 |
|||
| HY-104008 | MedChemExpress | 10mg | EUR 1731.63 |
|
Description: ACY-957 is an orally active and selective inhibitor of HDAC1 and HDAC2, with IC50s of 7 nM, 18 nM, and 1300 nM against HDAC1/2/3, respectively, and shows no inhibition on HDAC4/5/6/7/8/9[1]. |
|||
BM 957 |
|||
| HY-18106 | MedChemExpress | Get quote | Ask for price |
|
Description: BM 957 is a potent Bcl-2 and Bcl-xL inhibitor, with Kis of 1.2, <1 nM and IC50s of 5.4, 6.0 nM respectively. |
|||
BM 957 |
|||
| MBS3842851-10mg | MyBiosource | 10mg | EUR 615 |
